Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2017 07:00 ET | Source: Shield Therapeutics

Shield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study

LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces the completion of enrollment of the pivotal...
September 06, 2017 07:00 ET | Source: Shield Therapeutics

Shield Therapeutics plc ("Shield" or the "Group") US Composition of Matter Patent

LONDON, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that the United States Patent and...
August 31, 2017 09:00 ET | Source: Shield Therapeutics

Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017

LONDON, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive...
September 20, 2016 08:42 ET | Source: Shield Therapeutics

Interim Results for the six months ended 30 June 2016

LONDON, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces its preliminary Group results for...